Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study

Systemic Sclerosis Clinical Trial

— ITS-PILOT  

Official title:

Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03582800
• Other study ID #: I17004 (ITS-PILOT)
• Status: Recruiting
• Phase: Phase 2
• Start date: January 6, 2020
• Est. completion date: June 6, 2025

Study information

• Verified date: December 2023
• Source: University Hospital, Limoges
• Contact: Vincent GUIGONIS, MD
• Phone: 555056358
• Email: vincent.guigonis[@]unilim.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Ectopic soft tissue calcifications or ossifications can complicate the course of numerous diseases; most of them are rare or very rare. Even if the clinical, radiological and pathological presentation of ectopic calcifications and ossifications are different, the same hypotheses are discussed considering their hypothetical pathophysiology. Indeed, high calcium phosphate product, local cellular lesions and abnormal transdifferentiation of mesenchymal cells are regularly evoked when pathophysiology of such calcifications or ossifications are discussed. Apart from several case reports that have not been confirmed so far, no medical treatments are available, leading to significant pain and impairment of quality of life for patients. Therefore, only surgical treatment can be proposed when the volume or the consequences of these calcifications/ossifications become too important. Sodium thiosulfate (STS) is currently used as a cyanide poisoning antagonist and a chemoprotectant against adverse effects of several chemotherapies such as Cisplatin. Numerous case reports and several studies have revealed the potential interest of STS in the treatment of uremic induced vascular or soft tissues calcifications. Recently, our group has developed an expertise in the use of STS for the treatment of ectopic soft tissue calcifications or ossifications. Considering these promising preliminary data, and their limits, we developed a strategy to treat soft tissue calcifications or ossifications based on a local administration of STS. The first results of this therapeutic strategy are highly promising and the local or systemic safety is satisfactory so far. These preliminary data also reported by others deserve to be confirmed in a prospective study. We propose in this project to conduct a prospective open controlled phase II trial in order to assess the efficacy and the safety of intralesional administration of STS for the treatment of calcifications secondary to dermatomyositis or systemic sclerosis and ectopic ossifications secondary to pseudo-hypoparathyroidism 1a type (PHP1A/iPPSD2) (inactivating parathyroid hormone / parathyroid-hormone-related peptid (PTH/PTHrP) signalling disorder).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: June 6, 2025
• Est. primary completion date: June 6, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months and older

Eligibility

Inclusion Criteria:

• Patient presenting with:
• ectopic ossification secondary to iPPSD2 or
• ectopic calcification secondary to dermatomyositis or
• ectopic calcification secondary to systemic sclerosis
• Patient aged 2 years or over
• Indication of STS infusion validated by a multidisciplinary committee, based on the significant morbidity and/or functional impact of the targeted calcification/ossification
• Patient with no planned surgery of the calcifications/ossifications for the twelve coming months
• Women of childbearing potential on highly effective contraception (such as hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence)
• Men with women of childbearing potential partners should use condoms during the whole treatment period and until 91 days after the last injection.
• Informed consent signed by the patient / parents
• Patient affiliated to the social security system

Exclusion Criteria:

• Allergy to STS or one of the excipients used
• Contraindication to local injection of STS
• Anticoagulant therapy
• Pregnant, parturient or breastfeeding woman
• Patient deprived of freedom by a court judgment or an administrative decision
• Patient undergoing psychiatric care under coercion
• Legally protected adult patients (guardianship / curatorship)
• Patient unable to give consent
• Patient placed under judicial protection

Related Conditions & MeSH terms

• Calcinosis
• Dermatomyositis
• iPPSD2
• Scleroderma, Diffuse
• Scleroderma, Systemic
• Systemic Sclerosis

Intervention

Drug:
• STS
M0-M6 (run-in phase): medical care and follow-up as usual M6-M12 (STS phase): Patients with iPPSD2 will be treated with subcutaneous infusion using a portable pump. Patients with dermatomyositis or systemic sclerosis will be treated with repeated injections every two weeks. Patients will receive a maximal total number of 11 STS injections. M12: final visit (V5): clinical evaluation, photograph and CT scan of the treated lesion, pain and quality of life evaluation.

Locations

Country	Name	City	State
France	CHU de BORDEAUX	Bordeaux
France	Hospice Civil de Lyon	Bron
France	ApHp - Hôpital Bicêtre	Le Kremlin-Bicêtre
France	CHU de Limoges	Limoges
France	ApHp - hôpital Lariboisière	Paris
France	CHU de ROUEN	Rouen
France	CHU de Toulouse	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Limoges

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of the percentage of volume of the treated calcifications / ossifications	Calculation of percentage of volume evolution of the treated calcification / ossification between the beginning and the end of STS treatment, in each of the three diseases (dermatomyositis, systemic sclerosis and iPPSD2), evaluated on CT-scan measurements.	between Month 6 and Month 12
Secondary	Change of the volume of the treated calcifications / ossifications	Calculation of volume of the treated calcification / ossification at (i) inclusion, the end of the run-in period (6 month) and after 6 months of local injections of STS in each disease (12 month), evaluated on CT-scan measurements.	Month 0, Month 6 and Month 12
Secondary	Adverse events	Collection of adverse events (clinical and biological): causality, severity, and seriousness during the STS treatment.	Month 12
Secondary	Change of the Hounsfield density of the treated ectopic calcifications/ossifications	Hounsfield density analysis of the treated ectopic calcifications/ossifications at inclusion, the end of the run-in period (6 month) and after 6 months of local injections of STS (12 month), evaluated on CT-scan measurements.	Month 0, Month 6 and Month 12
Secondary	Change of the percentage of patient with a clinically pertinent variation in pain	Calculation of Percentage of patients with a clinically pertinent variation in pain evaluated with pain scales: difference in hetero-evaluation scale of pain in children (HEDEN) = 2 (2-7 years old) between M0-M6 and M6-M12	Between Month0 and Month 6 and Between Month 6 and Month 12
Secondary	Change of the percentage of patient with a clinically pertinent variation in pain	Calculation of Percentage of patients with a clinically pertinent variation in pain evaluated with pain scales: difference in visual analogue pain intensity scale (VAS) score = 2 (> 7 years old) between M0-M6 and M6-M12	Between Month0 and Month 6 and Between Month 6 and Month 12
Secondary	Change of the percentage of patients with a clinically pertinent variation in quality of life	Calculation of percentage of patients with a clinically pertinent variation in quality of life : difference in PedsQL = 5 (2-18 years old, using appropriates reports) between M0-M6 and M6-M12	Between Month0 and Month 6 and Between Month 6 and Month 12
Secondary	Change of the percentage of patients with a clinically pertinent variation in quality of life	Calculation of percentage of patients with a clinically pertinent variation in quality of life : difference in Short Form 36 (SF36) score = 20 (> 18 years old) between M0-M6 and M6-M12	Between Month0 and Month 6 and Between Month 6 and Month 12